Literature DB >> 15540204

Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry.

Margareta Ramström1, Igor Ivonin, Anders Johansson, Håkan Askmark, Karin E Markides, Roman Zubarev, Per Håkansson, Sten-Magnus Aquilonius, Jonas Bergquist.   

Abstract

This study demonstrates the power of a novel proteomic approach developed for the detection and identification of biological markers in body fluids. The goal was to observe alterations in the protein patterns of cerebrospinal fluid (CSF) related to amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder with unknown etiology. In the experiments, tryptic digests of CSF from patients and healthy controls were analyzed by on-line capillary liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. (FT-ICR MS) Typically, around 4000 peptides were detected in one such experiment, and a pattern recognition program was constructed for the data analysis to distinguish mass chromatograms from patients and controls. This strategy was evaluated comparing the peptide patterns of CSF spiked in vitro with a biomarker, with control CSF. The patterns were clearly separated and the tryptic peptides of the biomarker were successfully selected as characteristic peaks. Hence, the method was applied to compare mass chromatograms of CSF from 12 ALS-patients and 10 matched healthy controls. While no biomarker alone could be identified from the characteristic peaks, we were able to assign 4 out of 5 unknown samples correctly (i.e., 80% correctly diagnosed, 20% false-negative), and it would be 100% if we reject a possible outlier believed to be caused by an occlusion in the spinal CSF compartment. These findings are very promising, although the clinical relevance is not fully established due to the low number of unknown samples analyzed. In addition to the diagnostic potential, these results may be important steps towards understanding the neurodegenerative process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15540204     DOI: 10.1002/pmic.200400871

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  17 in total

Review 1.  Proteomics of human neurodegenerative diseases.

Authors:  Jing Zhang; C Dirk Keene; Catherine Pan; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

2.  Assessment of Protein Stability in Cerebrospinal Fluid Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Protein Profiling.

Authors:  Srikanth Ranganathan; Anna Polshyna; Georgina Nicholl; James Lyons-Weiler; Robert Bowser
Journal:  Clin Proteomics       Date:  2006-03-01       Impact factor: 3.988

Review 3.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

4.  Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Mahlon A Collins; Jiyan An; Brian L Hood; Thomas P Conrads; Robert P Bowser
Journal:  J Proteome Res       Date:  2015-10-08       Impact factor: 4.466

5.  Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.

Authors:  Runsheng Li; Yan Guo; Bang Ming Han; Xiaowei Yan; Angelita G Utleg; Wei Li; Lan Chun Tu; Jian Wang; Leroy Hood; Shujie Xia; Biaoyang Lin
Journal:  Proteomics Clin Appl       Date:  2008-04-01       Impact factor: 3.494

6.  Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.

Authors:  Srikanth Ranganathan; Eric Williams; Philip Ganchev; Vanathi Gopalakrishnan; David Lacomis; Leo Urbinelli; Kristyn Newhall; Merit E Cudkowicz; Robert H Brown; Robert Bowser
Journal:  J Neurochem       Date:  2005-12       Impact factor: 5.372

7.  Prion disease diagnosis by proteomic profiling.

Authors:  Allen Herbst; Sean McIlwain; Joshua J Schmidt; Judd M Aiken; C David Page; Lingjun Li
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

Review 8.  Biomarker discovery in neurodegenerative diseases: a proteomic approach.

Authors:  Min Shi; W Michael Caudle; Jing Zhang
Journal:  Neurobiol Dis       Date:  2008-09-26       Impact factor: 5.996

9.  Proteomic characterization of lipid raft proteins in amyotrophic lateral sclerosis mouse spinal cord.

Authors:  Jianjun Zhai; Anna-Lena Ström; Renee Kilty; Priya Venkatakrishnan; James White; William V Everson; Eric J Smart; Haining Zhu
Journal:  FEBS J       Date:  2009-05-05       Impact factor: 5.542

Review 10.  Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Authors:  Robert Bowser; David Lacomis
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.